Measurement of Crosslinked Fibrin Derivatives -Use in the Diagnosis of Venous Thrombosis

 

PDF Download Buy Article Permissions and Reprints

Summary

The measurement of crosslinked fibrin derivatives in plasma has received evaluation as a screening test in the diagnosis of venous thrombosis. Plasma samples were taken from 104 patients undergoing venography because of clinical suspicion of lower limb venous thrombosis. The samples were assayed using a monoclonal antibody identifying an epitope on D dimer and larger crosslinked fibrin derivatives in an enzyme immunoassay. 100% of patients with positive venograms had elevated levels of these molecules. While a percentage of patients with negative venograms also had increased levels, alternative clinical explanations were apparent in most. A normal D dimer value excludes the diagnosis of venous thrombosis, while an increased value supports it. The measurement of crosslinked fibrin derivatives in plasma may play a role in the selection of patients for venography.

• References

• 1 Bettman MA, Salzman EW. Recent advances in the diagnosis of deep vein thrombosis and pulmonary embolism. In: Recent Advances in Blood Coagulation. Poller L. (Ed.). Number 3 Churchill Livingstone; Edinburgh: 1981. pp 287-317
  Google Scholar
• 2 Tibbutt DA, Chesterman CN, Allinton MJ, Williams EW, Faulkner T. Measurement of fibrinogen-fibrin-related antigen in serum as aid to diagnosis of deep vein thrombosis in outpatients. Brit Med J 1975; 1: 367-369
  CrossrefPubMedGoogle Scholar
• 3 Cooke ED, Gordon YB, Bowcock SA, Sola CM, Pilcher MF, Chard T, Ibbotson RM, Ainsworth ME. Serum fibrin(ogen) degradation products in diagnosis of deep vein thrombosis and pulmonary embolism after hip surgery. Lancet 1975; ii 51-54
  PubMedGoogle Scholar
• 4 Butler MJ, Gordon YB, Irving MH, Sola CM, Chard T. Serum levels of fibrin(ogen) degradation fragment E antigen in the diagnosis of deep vein thrombosis after abdominal and inguinal surgery. Thromb Res 1976; 8: 167-171
  CrossrefPubMedGoogle Scholar
• 5 Gordon YB, Cooke ED, Bowcock SA, Ratky SM, Pilcher MF, Chard T. Non invasive screening for venous thromboembolic disease. Brit J Haem 1977; 35: 505-510
  CrossrefPubMedGoogle Scholar
• 6 Bynum LJ, Crotty CM, Wilson JE. Diagnostic value of tests of fibrin metabolism in patients predisposed to pulmonary embolism. Arch Intern Med 1979; 139: 283-285
  CrossrefPubMedGoogle Scholar
• 7 Foti ME, Gurewich V. Fibrin degradation products and plethysmography. Measurements in the diagnosis of acute deep vein thrombosis. Arch Intern Med 1980; 140: 903-906
  CrossrefPubMedGoogle Scholar
• 8 Johnston D WC, Scott AA, Glynn M FX. Tests for hemostasis and their relevance to venous thrombosis. Can J Surg 1980; 23: 373-380
  PubMedGoogle Scholar
• 9 Zielinsky A, Hirsh J, Straumanis G, Carter CJ, Gent M, Sackett DL, Hull R, Kelton JG, Powers P, Turpie AG. The diagnostic value of fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. Blood 1982; 59: 346-350
  PubMedGoogle Scholar
• 10 Mellbring G, Dahlgren S, Reiz S, Wiman B. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res 1983; 32: 575-584
  CrossrefPubMedGoogle Scholar
• 11 Gordon YB, Martin MJ, McNeile AT, Chard T. Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay. Lancet 1973; ii 1168-1170
  PubMedGoogle Scholar
• 12 Chen JP, Schulof RS. Radioimmunoassay of fibrinogen-fibrin degradation products: assay for fragment E-related neoantigen-methodological aspects. Thromb Res 1979; 16: 601-615
  CrossrefPubMedGoogle Scholar
• 13 Marder VJ, Francis CW. Plasmin degradation of crosslinked fibrin. Ann NY Acad Sci 1983; 408: 397-406
  CrossrefPubMedGoogle Scholar
• 14 Gaffney PJ. The occurrence and clinical relevance of fibrin fragments in blood. Ann NY Acad Sci 1983; 408: 407-422
  CrossrefPubMedGoogle Scholar
• 15 Graeff H, Hafter R. Detection and relevance of crosslinked fibrin derivatives in blood. Sem Thromb Hemostas 1982; 8: 57-68
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. Biochim Biophys Acta 1973; 295: 308-313
  CrossrefPubMedGoogle Scholar
• 17 Gaffney PJ. FDP. Lancet 1972; ii 1422
  PubMedGoogle Scholar
• 18 Rylatt DB, Blake AS, Cottis LE. et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
  CrossrefPubMedGoogle Scholar
• 19 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Hemostas 1983; 50: 591-594
  PubMedGoogle Scholar
• 20 Whitaker AN, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ, Bunce IH. Measurement of crosslinked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-887
  CrossrefPubMedGoogle Scholar
• 21 Lea Thomas M. Phlebography of the lower limb. Churchill Livingstone; Edinburgh: 1982. pp 25-38
• 22 Merskey C, Johnson AJ, Lalezari P. Increase in fibrinogen and fibrin related antigen in human serum due to vitro lysis of fibrin by thrombin. J Clin Invest 1972; 51: 903-911
  CrossrefPubMedGoogle Scholar
• 23 Gaffney PJ, Perry MJ. Unreliability of current serum fibrin degradation product (FDP) assays. Thromb Haemostas 1985; 53: 301-302
  PubMedGoogle Scholar
• 24 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Rapid detection of cross linked fibrin degradation products in plasma using monoclonal antibody coated latex particles. Amer J Clin Pathol 1986; 85: 360-364
  PubMedGoogle Scholar